<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00058825</url>
  </required_header>
  <id_info>
    <org_study_id>8713-HIMSUM</org_study_id>
    <nct_id>NCT00058825</nct_id>
  </id_info>
  <brief_title>Stem Cell Transplant for Hematologic Diseases</brief_title>
  <acronym>HIMSUM</acronym>
  <official_title>Phase I/II Study of Allogeneic Stem Cell Transplantation for Patients With Hematologic Diseases Using Haploidentical Family Donors and Sub-Myeloablative Conditioning With Campath 1H</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baylor College of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Texas Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Methodist Hospital System</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Baylor College of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients are being asked to participate in this study because they have a cancer in their
      blood, Fanconi's Anemia, or have been unsuccessfully treated for bone marrow failure such as
      Aplastic Anemia or Paroxysmal Nocturnal Hemoglobinuria. Any of these conditions could benefit
      from an allogeneic stem cell transplant using a donor that is related to the patient.

      Stem cells are created in the bone marrow. They grow into different types of blood cells that
      the patient needs, including red blood cells, white blood cells, and platelets. In a
      transplant, the patient's own stem cells are killed and then replaced by stem cells from the
      donor.

      Usually, patients are given very strong doses of chemotherapy prior to receiving a stem cell
      transplant. However, because of the patient's condition, they have a high risk of
      experiencing life-threatening treatment-related side-effects. Recently, some doctors have
      begun to use chemotherapy that does not cause as many side-effects before patients receive a
      transplant.

      This research study adds CAMPATH 1H to a low-dose chemotherapy regimen, followed by an
      allogeneic stem cell transplantation. We want to see whether adding CAMPATH 1H to the
      transplant medications helps in treating the disease. We also want to see whether there are
      fewer life-threatening side-effects from the treatment. CAMPATH 1H is a drug that is still
      being studied. CAMPATH 1H stays active in the body for a long time after patients receive it,
      which means it may work longer at preventing graft-versus-host-disease (GvHD) symptoms.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Before treatment begins, stem cells will be collected from the donor's blood or bone marrow.
      The stem cells will be collected and frozen before we start to give the patient chemotherapy.

      After admission to the hospital, patients will receive total body irradiation (very strong
      x-rays that kill cells in the bone marrow), Fludarabine and Campath 1H prior to the stem cell
      transplant (infusion of the donor's stem cells).

      Starting 7 days after the transplant, the patient will be given G-CSF by subcutaneous
      injection, until a blood test shows that numbers of granulocytes (a type of white blood cell)
      in the blood are more than 1,000/uL. This is to help increase blood cell counts.

      After transplantation, the patient will undergo several evaluations at different times. These
      are standard evaluations and tests performed for any patient who has received a stem cell
      transplant, as part of routine clinical monitoring.

      We will also be looking at the patient's immune function (how the body protects itself to
      prevent and fight infections and diseases). To do this, blood tests will be performed at
      regular intervals (every 3 to 6 months) for 2 years.

      Depending on how well the donor stem cells work in the body after the transplant, the patient
      may receive one or more Donor Leukocyte Infusions (DLI). This is when leukocytes (a type of
      white blood cell) collected from the same donor that provided the stem cells are given to the
      patient through a central line into a vein.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow accrual due to practice changes meant study would take too long to finish
  </why_stopped>
  <start_date>August 2000</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Transplant Related Mortality (TRM)</measure>
    <time_frame>100 days</time_frame>
    <description>Percentage of patients with transplant related mortality</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time in Days to ANC Engraftment</measure>
    <time_frame>30 days</time_frame>
    <description>Engraftment was defined as the day of absolute neutrophil counts (ANC) exceeded 0.5 X 10^9/L on the first of 3 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Donor Chimerism Engraftment of Greater Than 50%</measure>
    <time_frame>30 days</time_frame>
    <description>Number of patients that engrafted who showed a chimerism (donor cells) of greater than 50% in the first 30 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute Graft Versus Host Disease</measure>
    <time_frame>100 days</time_frame>
    <description>Number of patients with Acute Graft Versus Host Disease within 100 days post-transplant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chronic Graft Versus Host Disease</measure>
    <time_frame>1 year</time_frame>
    <description>Number of patients with Chronic Graft Versus Host Disease within 1 year post-transplant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2-year Relapse-free Survival</measure>
    <time_frame>2 years</time_frame>
    <description>Relapse-free survival (RFS) was calculated from the time of transplant to the date of relapse, death, or last follow-up, whichever occurred first. Survival data were analyzed by Kaplan-Meier method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2-year Overall Survival</measure>
    <time_frame>2 years</time_frame>
    <description>Overall survival (OS) was calculated from the time of transplant to death from any cause or censored at last follow-up. Survival data were analyzed by Kaplan-Meier method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Who Engrafted With the Isolex/CLINIMACs System</measure>
    <time_frame>30 days</time_frame>
    <description>Engraftment was defined as the day of absolute neutrophil counts (ANC) exceeded 0.5 X 10^9/L on the first of 3 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Time to Engraftment With the Isolex/CLINIMACs System</measure>
    <time_frame>30 days</time_frame>
    <description>Engraftment was defined as the day of absolute neutrophil counts (ANC) exceeded 0.5 X 10^9/L on the first of 3 days.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Hematologic Malignancies</condition>
  <arm_group>
    <arm_group_label>Stem Cell Transplant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Total body irradiation (TBI); Fludarabine and Campath 1H; FK506 or Cyclosporine; Stem Cell Transplant; G-CSF.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Campath 1H</intervention_name>
    <description>Day -5 to Day -2: Campath 1H dose schedule as per institutional SOP.</description>
    <arm_group_label>Stem Cell Transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Day -5 to Day -2: Fludarabine 30 mg/m2.</description>
    <arm_group_label>Stem Cell Transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Stem Cell Transplant</intervention_name>
    <description>Day 0: Donor stem cells infused.</description>
    <arm_group_label>Stem Cell Transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Total Body Irradiation (TBI)</intervention_name>
    <description>Day -6: Total body irradiation of 600 cGy as two doses without blocks at a rate of less than or equal to 10 cGy/minute.</description>
    <arm_group_label>Stem Cell Transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FK506 (Tacrolimus) or Cyclosporine</intervention_name>
    <description>Day -2: FK506 or Cyclosporine as medically indicated to prevent GvHD.</description>
    <arm_group_label>Stem Cell Transplant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:

          1. Diagnosis of myelodysplastic disorders; Fanconi's Anemia; Acute Myelogenous Leukemia
             (including secondary); Acute Lymphoblastic Leukemia; Multiple Myeloma; Plasma Cell
             Dyscrasia; lymphoproliferative disorders (Non-Hodgkin Lymphoma, Hairy Cell Leukemia,
             Chronic Lymphocytic Leukemia, and Hodgkin's Disease). Diagnosis of myelodysplastic
             disorders which is not good risk by IPSS: Fanconi's Anemia; Acute Myelogenous Leukemia
             (1st or subsequent relapse, or 2nd or subsequent CR, or refractory disease); Acute
             Lymphoblastic Leukemia in 2nd or subsequent remission or relapse or refractory
             disease; Philadelphia Chromosome-positive Chronic Myelogenous Leukemia (failed STI and
             interferon); Multiple Myeloma (Stage II or III); Lymphoma; Chronic Lymphocytic
             Leukemia (primary refractory or recurrent disease); Hodgkin's Disease (after relapse);
             Hemophagocytic Lymphohistiocytosis (failed chemotherapy and/or anti-viral therapy);
             bone marrow failure such as Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria;
             PNH (failed prior therapies).

          2. Conditions that increase treatment related mortality: (need one or more to be
             eligible): Age &gt; / = 50 years; EF of less than 45%; DLCO less than 50% or FEVI 50-75%
             of predicted value; Diabetes Mellitus; Renal Insufficiency (but creatinine clearance
             not less than 25 mL/min); Prior recent history of systemic fungal infection; 3rd or
             greater remission of AML or ALL; Significant Grade III or IV neurologic or hepatic
             toxicity from previous treatment; More than 1 year from diagnosis (CML or Myeloma
             patients ONLY); Multiple types of treatment regimens (equal to or more than 3);
             Significant Grade III or IV neurologic or hepatic toxicity from previous treatment;
             Prior autologous or allogeneic stem cell transplantation.

          3. Haploidentical family member donor. This protocol is open to patients who lack a 5/6
             or 6/6 HLA antigen-matched donor. Due to the increased risk of GvHD, patients with
             Fanconi Anemia and a 5/6 HLA match will also be eligible.

             For this protocol, the &quot;best&quot; donor will be defined as a first-degree haploidentical
             family member who matches at the greatest number of MHC loci. Matching will be
             determined by Class I and Class II DNA typing. The donor should be sufficiently
             healthy as to not be at increased risk from the stem cell mobilization procedure.
             Should more than one &quot;equally&quot; MHC-incompatible donor be identified, other selection
             criteria will include: age and size of donor, CMV status, and sex. The Principal
             Investigator will make final decisions.

          4. Available healthy donor without any contraindications for donation.

          5. Patient and/or legal representative and/or legal guardian able to understand and sign
             consent.

          6. Age between birth and 70 years.

          7. Women of child-bearing potential must have a negative pregnancy test.

        EXCLUSION CRITERIA:

          1. Pregnant, lactating or unwilling to use contraception.

          2. HIV-positive patient.

          3. Uncontrolled intercurrent infection.

          4. Untreated blast crisis for CML.

          5. Uncontrolled high-grade lymphoproliferative disease / lymphoma.

          6. Unstable angina and uncompensated congestive heart failure (Zubrod of 3 or greater).

          7. Severe chronic pulmonary disease requiring oxygen (Zubrod of 3 or greater).

          8. Hemodialysis dependent.

          9. Active hepatitis or cirrhosis with total bilirubin, SGOT, and SGPT greater than 3X
             upper limit of normal.

         10. Unstable cerebral vascular disease and recent hemorrhagic stroke (less than 6 months).

         11. Active CNS disease from hematological disorder.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>George Carrum, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baylor College of Medicine; The Methodist Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Methodist Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 11, 2003</study_first_submitted>
  <study_first_submitted_qc>April 14, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2003</study_first_posted>
  <results_first_submitted>September 23, 2015</results_first_submitted>
  <results_first_submitted_qc>September 23, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 22, 2015</results_first_posted>
  <last_update_submitted>September 20, 2016</last_update_submitted>
  <last_update_submitted_qc>September 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Baylor College of Medicine</investigator_affiliation>
    <investigator_full_name>George Carrum</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Campath</keyword>
  <keyword>stem cell transplant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hematologic Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Alemtuzumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Stem Cell Transplant</title>
          <description>Total body irradiation (TBI); Fludarabine and Campath 1H; FK506 or Cyclosporine; Stem Cell Transplant; G-CSF.
Campath 1H: Day -5 to Day -2: Campath 1H dose schedule as per institutional SOP.
Fludarabine: Day -5 to Day -2: Fludarabine 30 mg/m2.
Stem Cell Transplant: Day 0: Donor stem cells infused.
Total Body Irradiation (TBI): Day -6: Total body irradiation of 600 cGy as two doses without blocks at a rate of less than or equal to 10 cGy/minute.
FK506 (Tacrolimus) or Cyclosporine: Day -2: FK506 or Cyclosporine as medically indicated to prevent GvHD.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Relapse</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Progressive Disease</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Graft Failure</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Stem Cell Transplant</title>
          <description>Total body irradiation (TBI); Fludarabine and Campath 1H; FK506 or Cyclosporine; Stem Cell Transplant; G-CSF.
Campath 1H: Day -5 to Day -2: Campath 1H dose schedule as per institutional SOP.
Fludarabine: Day -5 to Day -2: Fludarabine 30 mg/m2.
Stem Cell Transplant: Day 0: Donor stem cells infused.
Total Body Irradiation (TBI): Day -6: Total body irradiation of 600 cGy as two doses without blocks at a rate of less than or equal to 10 cGy/minute.
FK506 (Tacrolimus) or Cyclosporine: Day -2: FK506 or Cyclosporine as medically indicated to prevent GvHD.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="27"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15" lower_limit="2" upper_limit="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Transplant Related Mortality (TRM)</title>
        <description>Percentage of patients with transplant related mortality</description>
        <time_frame>100 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Stem Cell Transplant</title>
            <description>Total body irradiation (TBI); Fludarabine and Campath 1H; FK506 or Cyclosporine; Stem Cell Transplant; G-CSF.
Campath 1H: Day -5 to Day -2: Campath 1H dose schedule as per institutional SOP.
Fludarabine: Day -5 to Day -2: Fludarabine 30 mg/m2.
Stem Cell Transplant: Day 0: Donor stem cells infused.
Total Body Irradiation (TBI): Day -6: Total body irradiation of 600 cGy as two doses without blocks at a rate of less than or equal to 10 cGy/minute.
FK506 (Tacrolimus) or Cyclosporine: Day -2: FK506 or Cyclosporine as medically indicated to prevent GvHD.</description>
          </group>
        </group_list>
        <measure>
          <title>Transplant Related Mortality (TRM)</title>
          <description>Percentage of patients with transplant related mortality</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>97.5% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time in Days to ANC Engraftment</title>
        <description>Engraftment was defined as the day of absolute neutrophil counts (ANC) exceeded 0.5 X 10^9/L on the first of 3 days.</description>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Stem Cell Transplant</title>
            <description>Total body irradiation (TBI); Fludarabine and Campath 1H; FK506 or Cyclosporine; Stem Cell Transplant; G-CSF.
Campath 1H: Day -5 to Day -2: Campath 1H dose schedule as per institutional SOP.
Fludarabine: Day -5 to Day -2: Fludarabine 30 mg/m2.
Stem Cell Transplant: Day 0: Donor stem cells infused.
Total Body Irradiation (TBI): Day -6: Total body irradiation of 600 cGy as two doses without blocks at a rate of less than or equal to 10 cGy/minute.
FK506 (Tacrolimus) or Cyclosporine: Day -2: FK506 or Cyclosporine as medically indicated to prevent GvHD.</description>
          </group>
        </group_list>
        <measure>
          <title>Time in Days to ANC Engraftment</title>
          <description>Engraftment was defined as the day of absolute neutrophil counts (ANC) exceeded 0.5 X 10^9/L on the first of 3 days.</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12" lower_limit="6" upper_limit="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Donor Chimerism Engraftment of Greater Than 50%</title>
        <description>Number of patients that engrafted who showed a chimerism (donor cells) of greater than 50% in the first 30 days</description>
        <time_frame>30 days</time_frame>
        <population>Patients engrafted</population>
        <group_list>
          <group group_id="O1">
            <title>Stem Cell Transplant</title>
            <description>Total body irradiation (TBI); Fludarabine and Campath 1H; FK506 or Cyclosporine; Stem Cell Transplant; G-CSF.
Campath 1H: Day -5 to Day -2: Campath 1H dose schedule as per institutional SOP.
Fludarabine: Day -5 to Day -2: Fludarabine 30 mg/m2.
Stem Cell Transplant: Day 0: Donor stem cells infused.
Total Body Irradiation (TBI): Day -6: Total body irradiation of 600 cGy as two doses without blocks at a rate of less than or equal to 10 cGy/minute.
FK506 (Tacrolimus) or Cyclosporine: Day -2: FK506 or Cyclosporine as medically indicated to prevent GvHD.</description>
          </group>
        </group_list>
        <measure>
          <title>Donor Chimerism Engraftment of Greater Than 50%</title>
          <description>Number of patients that engrafted who showed a chimerism (donor cells) of greater than 50% in the first 30 days</description>
          <population>Patients engrafted</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Acute Graft Versus Host Disease</title>
        <description>Number of patients with Acute Graft Versus Host Disease within 100 days post-transplant</description>
        <time_frame>100 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Stem Cell Transplant</title>
            <description>Total body irradiation (TBI); Fludarabine and Campath 1H; FK506 or Cyclosporine; Stem Cell Transplant; G-CSF.
Campath 1H: Day -5 to Day -2: Campath 1H dose schedule as per institutional SOP.
Fludarabine: Day -5 to Day -2: Fludarabine 30 mg/m2.
Stem Cell Transplant: Day 0: Donor stem cells infused.
Total Body Irradiation (TBI): Day -6: Total body irradiation of 600 cGy as two doses without blocks at a rate of less than or equal to 10 cGy/minute.
FK506 (Tacrolimus) or Cyclosporine: Day -2: FK506 or Cyclosporine as medically indicated to prevent GvHD.</description>
          </group>
        </group_list>
        <measure>
          <title>Acute Graft Versus Host Disease</title>
          <description>Number of patients with Acute Graft Versus Host Disease within 100 days post-transplant</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Grade 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade IV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Chronic Graft Versus Host Disease</title>
        <description>Number of patients with Chronic Graft Versus Host Disease within 1 year post-transplant</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Stem Cell Transplant</title>
            <description>Total body irradiation (TBI); Fludarabine and Campath 1H; FK506 or Cyclosporine; Stem Cell Transplant; G-CSF.
Campath 1H: Day -5 to Day -2: Campath 1H dose schedule as per institutional SOP.
Fludarabine: Day -5 to Day -2: Fludarabine 30 mg/m2.
Stem Cell Transplant: Day 0: Donor stem cells infused.
Total Body Irradiation (TBI): Day -6: Total body irradiation of 600 cGy as two doses without blocks at a rate of less than or equal to 10 cGy/minute.
FK506 (Tacrolimus) or Cyclosporine: Day -2: FK506 or Cyclosporine as medically indicated to prevent GvHD.</description>
          </group>
        </group_list>
        <measure>
          <title>Chronic Graft Versus Host Disease</title>
          <description>Number of patients with Chronic Graft Versus Host Disease within 1 year post-transplant</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>2-year Relapse-free Survival</title>
        <description>Relapse-free survival (RFS) was calculated from the time of transplant to the date of relapse, death, or last follow-up, whichever occurred first. Survival data were analyzed by Kaplan-Meier method.</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Stem Cell Transplant</title>
            <description>Total body irradiation (TBI); Fludarabine and Campath 1H; FK506 or Cyclosporine; Stem Cell Transplant; G-CSF.
Campath 1H: Day -5 to Day -2: Campath 1H dose schedule as per institutional SOP.
Fludarabine: Day -5 to Day -2: Fludarabine 30 mg/m2.
Stem Cell Transplant: Day 0: Donor stem cells infused.
Total Body Irradiation (TBI): Day -6: Total body irradiation of 600 cGy as two doses without blocks at a rate of less than or equal to 10 cGy/minute.
FK506 (Tacrolimus) or Cyclosporine: Day -2: FK506 or Cyclosporine as medically indicated to prevent GvHD.</description>
          </group>
        </group_list>
        <measure>
          <title>2-year Relapse-free Survival</title>
          <description>Relapse-free survival (RFS) was calculated from the time of transplant to the date of relapse, death, or last follow-up, whichever occurred first. Survival data were analyzed by Kaplan-Meier method.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.9" lower_limit="11.5" upper_limit="43.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>2-year Overall Survival</title>
        <description>Overall survival (OS) was calculated from the time of transplant to death from any cause or censored at last follow-up. Survival data were analyzed by Kaplan-Meier method.</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Stem Cell Transplant</title>
            <description>Total body irradiation (TBI); Fludarabine and Campath 1H; FK506 or Cyclosporine; Stem Cell Transplant; G-CSF.
Campath 1H: Day -5 to Day -2: Campath 1H dose schedule as per institutional SOP.
Fludarabine: Day -5 to Day -2: Fludarabine 30 mg/m2.
Stem Cell Transplant: Day 0: Donor stem cells infused.
Total Body Irradiation (TBI): Day -6: Total body irradiation of 600 cGy as two doses without blocks at a rate of less than or equal to 10 cGy/minute.
FK506 (Tacrolimus) or Cyclosporine: Day -2: FK506 or Cyclosporine as medically indicated to prevent GvHD.</description>
          </group>
        </group_list>
        <measure>
          <title>2-year Overall Survival</title>
          <description>Overall survival (OS) was calculated from the time of transplant to death from any cause or censored at last follow-up. Survival data were analyzed by Kaplan-Meier method.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3" lower_limit="16.8" upper_limit="50.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Who Engrafted With the Isolex/CLINIMACs System</title>
        <description>Engraftment was defined as the day of absolute neutrophil counts (ANC) exceeded 0.5 X 10^9/L on the first of 3 days.</description>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Isolex</title>
            <description>The Isolex system was used for cell selection.</description>
          </group>
          <group group_id="O2">
            <title>CLINIMACs</title>
            <description>The CLINIMACS CD34 Reagent system was used for cell selection.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Who Engrafted With the Isolex/CLINIMACs System</title>
          <description>Engraftment was defined as the day of absolute neutrophil counts (ANC) exceeded 0.5 X 10^9/L on the first of 3 days.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Time to Engraftment With the Isolex/CLINIMACs System</title>
        <description>Engraftment was defined as the day of absolute neutrophil counts (ANC) exceeded 0.5 X 10^9/L on the first of 3 days.</description>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Isolex</title>
            <description>The Isolex system was used for cell selection.</description>
          </group>
          <group group_id="O2">
            <title>CLINIMACs</title>
            <description>The CLINIMACS CD34 Reagent system was used for cell selection.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Time to Engraftment With the Isolex/CLINIMACs System</title>
          <description>Engraftment was defined as the day of absolute neutrophil counts (ANC) exceeded 0.5 X 10^9/L on the first of 3 days.</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12" lower_limit="6" upper_limit="21"/>
                    <measurement group_id="O2" value="12" lower_limit="9" upper_limit="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected until 30 days after autologous transplants and until 100 days after allogeneic transplants.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Stem Cell Transplant</title>
          <description>Total body irradiation (TBI); Fludarabine and Campath 1H; FK506 or Cyclosporine; Stem Cell Transplant; G-CSF.
Campath 1H: Day -5 to Day -2: Campath 1H dose schedule as per institutional SOP.
Fludarabine: Day -5 to Day -2: Fludarabine 30 mg/m2.
Stem Cell Transplant: Day 0: Donor stem cells infused.
Total Body Irradiation (TBI): Day -6: Total body irradiation of 600 cGy as two doses without blocks at a rate of less than or equal to 10 cGy/minute.
FK506 (Tacrolimus) or Cyclosporine: Day -2: FK506 or Cyclosporine as medically indicated to prevent GvHD.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (2.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Failure to engraft</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection (documented clinically or microbiologically) with grade 3 or 4 neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Infection without neutropenia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (2.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Failure to engraft</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Transfusion: Platelets</sub_title>
                <counts group_id="E1" events="16" subjects_affected="7" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="7" subjects_affected="3" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain or Cramping</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Bone Pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>GGT (Gamma-Glutamyl transpeptidase)</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>SGPT (ALT) (serum glutamic pyruvic transaminase)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Catheter-related infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Febrile Neutropenia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Infection (documented clinically or microbiologically) with grade 3 or 4 neutropenia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="8" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Infection without neutropenia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="5" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea (shortness of breath)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>George Carrum, MD</name_or_title>
      <organization>Baylor College of Medicine</organization>
      <email>GCarrum@houstonmethodist.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

